Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 4 47-4, 2003, Pages

  Brand, Christian L ^a   Sturis, Jeppe ^a   Gotfredsen, Carsten F ^a   Fleckner, Jan ^a   Fledelius, Christian ^a   Hansen, Bo F ^a   Andersen, Birgitte ^a   Ye, Ji Ming ^b   Sauerberg, Per ^a   Wassermann, Karsten ^a  

^a NOVO NORDISK A S   (Denmark)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Euglycemic clamp; Peroxisome proliferator activated receptor; Ragaglitazar; Rosiglitazone; Type 2 diabetes; Zucker diabetic fatty

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAGAGLITAZAR; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CELL RECEPTOR; FATTY ACID; GLYCOGEN; GLYCOSYLATED HEMOGLOBIN; OXAZINE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; BODY COMPOSITION; BODY WEIGHT; CYTOLOGY; EATING; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; PANCREAS ISLET; ZUCKER RAT;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; GLYCOGEN; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIVER; MALE; OXAZINES; PHENYLPROPIONATES; RATS; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037376448     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00348.2002     Document Type: Article

References (54)

1. Andersen B, Rassov A, Westergaard N, and Lundgren K. Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-D-arabinitol. Biochem J 342: 545-550, 1999.
2. Armstrong RB and Phelps RO. Muscle fiber type composition of the rat hindlimb. Am J Anat 171: 259-272, 1984.
3. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, and Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23: 1605-1611, 2000.
4. Berger J and Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
5. Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, and Newton RS. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 39: 17-30, 1998.
6. Bligh ED and Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
7. Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, and Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity [2]. J Med Chem 42: 3785-3788, 1999.
8. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, and Thurlby PL. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37: 3977-3985, 1994.
9. Chalkley SM, Hettiarachchi M, Chisholm DJ, and Kraegen EW. Long-term high-fat feeding leads to severe insulin resistance but not diabetes in Wistar rats. Am J Physiol Endocrinol Metab 282: E1231-E1238, 2002.
10. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15: 430-441, 1992.
11. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, and Paterniti JR. Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism 50: 963-971, 2001.
12. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.
13. DeFronzo RA, Bonadonna RC, and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318-368, 1992.
14. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR, Ogilvie KM, Liu S, and Kauffman RF. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51: 1083-1087, 2002.
15. Ferré P, Leturque A, Burnol AF, Penicaud L, and Girard J. A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. Biochem J 228: 103-110, 1985.
16. Franckhauser S, Munoz S, Pujol A, Casellas A, Riu E, Otaegui P, Su BL, and Bosch F. Increased fatty acid reesterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance. Diabetes 51: 624-630, 2002.
17. Gerich JE. Is insulin resistance the principal cause of type 2 diabetes? Diabetes Obes Metab 1: 257-263, 1999.
18. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, and Staels B. Peroxisome proliferatoractivated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000.
19. Hansen BF, Derave W, Jensen P, and Richter EA. No limiting role for glycogenin in determining maximal attainable glycogen levels in rat skeletal muscle. Am J Physiol Endocrinol Metab 278: E398-E404, 2000.
20. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, and Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96: 11513-11518, 1999.
21. James DE, Jenkins AB, and Kraegen EW. Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. Am J Physiol Endocrinol Metab 248: E567-E574, 1985.
22. Johansen T, Deckert M, Mandrup-Poulsen T, and Malmlof K. The role of growth hormone and glucocorticoid in glucose handling in vivo. J Endocrinol 162: 87-93, 1999.
23. Jones IR, Swai A, Taylor R, Miller M, Laker MF, and Alberti KG. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13: 855-863, 1990.
24. Kim H, Kim J, Kim S, Cha JY, Kim KS, and Ahn Y. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49: 1517-1524, 2000.
25. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, and Ahn YH. Peroxisomal proliferatoractivated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 51: 676-685, 2002.
26. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, and Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care 11: 495-499, 1988.
27. Larsen MO, Wilken M, Gotfredsen CF, Carr RD, Svendsen O, and Rolin B. Mild streptozotocin diabetes in the Gottingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab 282: E1342-E1351, 2002.
28. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Mamidi NVSR, and Rajagopalan R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 44:2675-2678, 2001.
29. Maddaiah VT and Madsen NB. Kinetics of purified liver phosphorylase. J Biol Chem 241: 3873-3881, 1966.
30. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, and Kadowaki T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847, 1998.
31. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, and Kashiwagi A. Amelioration of high fructose-induced metabolic derangements by activation of PPARα. Am J Physiol Endocrinol Metab 282: E1180-E1190, 2002.
32. Oakes ND, Thalen PG, Jacinto SM, and Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50: 1158-1165, 2001.
33. O'Doherty RM, Halseth AE, Granner DK, Bracy DP, and Wasserman DH. Analysis of insulin-stimulated skeletal muscle glucose uptake in conscious rat using isotopic glucose analogs. Am J Physiol Endocrinol Metab 274: E287-E296, 1998.
34. Petersen JS, Shalmi M, Lam HR, and Christensen S. Renal response to furosemide in conscious rats: effects of acute instrumentation and peripheral sympathectomy. J Pharmacol Exp Ther 258: 1-7, 1991.
35. Porte D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 17: 181-188, 2001.
36. Randle PJ, Garland P, Hales CN, and Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
37. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
38. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, and Knudsen LB. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283: E745-E752, 2002.
39. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Woldike HF, Fleckner J, Andersen AST, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, and Wulff EM. Novel tricyclicalpha-alkyloxyphenylpropionic acids: Dual PPAR alpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 45: 789-804, 2002.
40. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, and Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 130: 495-504, 2000.
41. Smith SA, Lister CA, Toseland CDN, and Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes 2: 363-372, 2000.
42. Somogyi M. Determination of blood sugar. J Biol Chem 160: 69-73, 1945.
43. Sparks JD, Shaw WN, Corsetti JP, Bolognino M, Pesek JF, and Sparks CE. Insulin-treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity. Metabolism 49: 1424-1430, 2000.
44. Sreenan S, Sturis J, Pugh W, Burant CF, and Polonsky KS. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol Endocrinol Metab 271: E742-E747, 1996.
45. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998.
46. Steele R, Wall JS, De Bodo RC, and Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1965.
47. Sturis J, Pugh WL, Tang J, and Polonsky KS. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am J Physiol Endocrinol Metab 269: E786-E792, 1995.
48. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-870, 1995.
49. Werner AL and Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21: 1082-1099, 2001.
50. Willson TM, Brown PJ, Sternbach DD, and Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550, 2000.
51. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, and Lehmann JM. The structure- activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996.
52. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, and Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 42:1543-1551, 2001.
53. Ye J, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, and Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-and alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50:411-417, 2001.
54. Ye J, Iglesias MA, Watson DG, Wood L, Jensen PB, Sørensen RV, Larsen PJ, Cooney GJ, Wassermann K, and Kraegen EW. PPARα/γ agonist ragaglitazar eliminates fatty liver and insulin resistance in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284: E531-E540, 2003.